MedTrace Logo

Open-Label Extension Study to Assess GLM101 in PMM2-CDG Patients

NCT06657859 · Status: ENROLLING_BY_INVITATION · Phase: PHASE2 · Type: INTERVENTIONAL · Enrollment: 90

Last updated 2026-03-02

No results posted yet for this study

Summary

The goal of this clinical trial is to provide continued access to GLM101 to treat PMM2-CDG in people who have previously received GLM101 in other trials and learn about the long term effect of GLM101. Participants will complete weekly infusions of GLM101 at the same dose level received in previous trials.

Conditions

  • Pmm2-CDG
  • Phosphomannomutase 2 Deficiency

Interventions

DRUG

GLM101

GLM101 IV infusion

Sponsors & Collaborators

  • Glycomine, Inc.

    lead INDUSTRY

Principal Investigators

  • Chief Medical Officer · Glycomine, Inc.

Study Design

Allocation
NA
Purpose
TREATMENT
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Min Age
2 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2024-09-30
Primary Completion
2029-09-30
Completion
2029-10-31
FDA Drug
Yes

Countries

  • Spain
  • United Kingdom

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT06657859 on ClinicalTrials.gov